Triple inhaled therapy for chronic obstructive pulmonary disease

Paolo Montuschi, Mario Malerba, Giuseppe Macis, Nadia Mores, Giuseppe Santini

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

29 Citazioni (Scopus)


Combining individual drugs in a single inhaler is the most convenient way to deliver triple therapy. A long-acting muscarinic receptor antagonist (LAMA) added to an inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA) fixed-dose combination (FDC) can improve efficacy of pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD). New inhaled ICS/LABA/LAMA FDCs, including fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium and beclometasone/formoterol/glycopyrronium, are in Phase III of clinical development for COPD. Triple inhaled therapy might be particularly useful in patients with severe to very severe COPD, above all in those with peripheral blood or sputum eosinophilia, asthma-COPD overlap syndrome (ACOS) or frequent exacerbators. Future prospective studies should assess efficacy and safety of triple ICS/LABA/LAMA therapy in selected COPD phenotypes.
Lingua originaleEnglish
pagine (da-a)1820-1827
Numero di pagine8
RivistaDrug Discovery Today
Stato di pubblicazionePubblicato - 2016


  • LAMA
  • chronic obstructive pulmonary disease (COPD)
  • inhaled corticosteroids
  • triple inhaled therapy


Entra nei temi di ricerca di 'Triple inhaled therapy for chronic obstructive pulmonary disease'. Insieme formano una fingerprint unica.

Cita questo